Results 131 to 140 of about 2,579,690 (304)
BNC2 exhibits context‐dependent opposing functions across multiple cancer types. This study reveals BNC2 as an oncogenic driver of melanoma proliferation and metastasis through transcriptional activation of PIK3CA. The natural compound TSN simultaneously degrades BNC2 and its oncogenic partner SMAD3 via CRBN‐dependent ubiquitination.
Hui Dai +7 more
wiley +1 more source
Diffuse Melanosis Cutis Under Immuno‐ and Targeted Therapy
In patients with highly advanced melanoma, rarely a diffuse melanosis cutis (DMC) can be noticed. Even though the condition is generally harmless itself, it can have a significant impact on the patient's well‐being as an obvious mark of the disease.
Christiane Cussigh +3 more
doaj +1 more source
Summary: Background: Diagnosis and treatment of advanced melanoma during pregnancy represents a major challenge, with scarce data on outcome or management available. Therefore, the Melanoma Pregnancy Taskforce collected real-world data to understand the
Jessica S.W. Borgers +36 more
doaj +1 more source
Spatiotemporal Multi‐Omic Mapping Reveals Liver‐Muscle Metabolic Crosstalk in Cancer Cachexia
The interactive CCAtlas platform delineates cross‐species, spatiotemporal, and sex‐specific molecular dynamics and metabolic rewiring across organs during cancer cachexia. Hepatic Gamt downregulation curtails hepatic creatine synthesis to trigger systemic creatine insufficiency and consequent skeletal muscle atrophy in LLC tumour‐bearing mice ...
Zihan Tian +12 more
wiley +1 more source
Advanced skin melanoma – systemic treatment [PDF]
In Poland, morbidity and mortality rates for melanoma are constantly increasing. In the case of inoperable disease or distant metastases, prognosis remains poor. For many years, dacarbazine has been the gold standard in systemic treatment.
Ziobro, Marek +3 more
core
Melanoma is the most deadly cutaneous malignancy; its incidence has risen significantly over the last 30 years and there is no effective treatment for advanced melanoma.
Ozen, Mustafa, Ittmann, M, Medreano, EE
core +1 more source
BackgroundTargeted therapies and immunotherapy are currently considered the mainstay first-line treatment for advanced BRAF-mutated melanoma. However, the impact of treatment (targeted therapy and immunotherapy) and the prognostic factors are still not ...
Chen Sun +8 more
doaj +1 more source
Macrophage Trogocytosis of Tumor Cells Drives the Immunosuppression of Tumor Microenvironment
Trogocytosis efficiency varies significantly among different tumor cells and is inversely related to their cortical stiffness; this efficiency dictates the extent of immunosuppression via upregulation of CXCL5 and Arg‐1, ultimately driving CD8+T cell exhaustion and tumor escape.
Chao Liang +9 more
wiley +1 more source
AMT‐676 is a novel antibody‐drug conjugate targeting CDH17, an adhesion molecule uniquely exposed on gastrointestinal tumor surfaces. Engineered with an optimized exatecan payload, it demonstrates profound tumor regression and a robust bystander effect across diverse preclinical models.
Ying‐nan Wang +21 more
wiley +1 more source
The DLST K409 succinylation mediated by CPT1A promotes OXPHOS and redox homeostasis through regulating enzyme activity, thereby promoting the malignant progression of LUAD. Notably, the succinylation of DLST can enhance the cuproptosis resistance by inhibiting its lipoylation.
Xuanxuan Li +9 more
wiley +1 more source

